Chemistry Department, Faculty of Arts and Science, Dumlupınar University, 43100 Kütahya, Turkey.
Università degli Studi di Firenze, NEUROFARBA Dept., Sezione di Scienze Farmaceutiche e Nutraceutiche, 50019 Sesto Fiorentino, Florence, Italy.
Bioorg Chem. 2018 Apr;77:101-105. doi: 10.1016/j.bioorg.2017.12.035. Epub 2018 Jan 2.
Herein, we report that acridine intermediates 5 were obtained from the reduction of nitro acridine derivatives 4, which were synthesized via condensation of dimedone, p-nitrobenzaldehyde with 4-amino-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)benzamide, respectively. Then acridine sulfonamide/carboxamide (7a-i) compounds were synthesized by reaction of amino acridine 5 with sulfonyl chlorides and carbamoyl chlorides. The new compounds were characterized by melting points, FT-IR, H NMR, C NMR and HRMS analyzes. The evaluation of in vitro test of the synthesized compounds against hCA I, II, IV and VII showed that some of them are potent inhibitors. Among them, compound 7e showed the most potent activity against hCA II with a K of 7.9 nM.
在此,我们报告说,吖啶中间体 5 是通过还原硝基吖啶衍生物 4 获得的,4 是分别通过二亚甲基酮、对硝基苯甲醛与 4-氨基-N-(5-磺酰胺基-1,3,4-噻二唑-2-基)苯甲酰胺缩合合成的。然后,吖啶磺酰胺/酰胺(7a-i)化合物通过吖啶 5 与磺酰氯和碳酰氯的反应合成。新化合物的特征在于熔点、FT-IR、H NMR、C NMR 和 HRMS 分析。对合成化合物对 hCA I、II、IV 和 VII 的体外测试评估表明,其中一些具有很强的抑制活性。其中,化合物 7e 对 hCA II 的抑制活性最强,K 值为 7.9 nM。